Peptide administration for lung fibrosis treatment using formulation based on medusa technology. develop a sustained release formulation os p144 or p17, loquid or freeze-dried form, for subcutaneous administration route and carry on preclinical and clinical trials.
Invitrotek ltd. Sti. (Istanbul, turkey) and pronto diagnostics ltd. (Tel aviv, israel) will collaborate in developing an assay, based on the targeted next generation sequencing to detect mutations in all thalassemia cases.
To investigate the possibility of developing biomarkers for hcc prognosis and companion diagnostics by using advanced sequencing technologies (ngs) and the data analysis algorithms for a set of target biomarkers.
To discover and develop a natural product for the management of a specific plant disease - "fire blight" - offering an alternative or complementary approach to the use of chemical control.
A study to develop a device & algorithm to analyze oxidative stress & proteomic profile in a ivf laboratory and investigate and validate the use of both as biomarkers for embryo viability in human ivf and its use as an additional markers to the existing morphokinetics markers provided by time lapse
The primary goal of the project evita is to develop an innovative dermatological product formulation dermavit for treatment of specific severe cutaneous side effects induced by therapy in oncology patients and to improve their quality of life.
The project aims for the development of a new legume variety that will bring agronomic sustainability and gives the starting material for a new and healthy bakery and feed products.
The project aims the development of generic purification procedures to obtain endotoxin standards, the development of analytical test kits to quantify endotoxins in liquid formulations and the development of endotoxin specific filter materials to purify liquid formulations from endotoxins.
To develop a simulation testing environment to reduce bioburden in interior spaces by high-efficient filter elements, which are investigated with the help of sensitive in vitro assays and biomarkers derived by data mining and other detection systems.
Therabodc aims at discovery of specific antibody fragments targeting g protein coupled receptors up regulated in tumor cells. The 2nd step is conjugating several anti-cancer drugs to the discovered antibody fragments. The 3rd is validating efficacy of combined molecules in cellular and animal model.